Yu-Feng Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yu-Feng Li has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Cheng-Hua Yu
Zunhua People's Hospital, Zunhua, China
1 shared publicationDe-Yan Li
Zunhua People's Hospital, Zunhua, China
1 shared publicationGuo-Hong Zheng
Department of Chemoradiotherapy, Tangshan People’s Hospital, No. 65, Shengli Road, Lunan District, Tangshan, 063000, Hebei Province, China
1 shared publicationJiang-Sheng Mi
Zunhua People's Hospital, Zunhua, China
1 shared publicationJing-Jing Liu
Department of Chemoradiotherapy, Tangshan People’s Hospital, No. 65, Shengli Road, Lunan District, Tangshan, 063000, Hebei Province, China
1 shared publication- Jinghua Zhang
North China University of Science and Technology; North China University of Science and Technology Affiliated Tangshan Maternal and Child Health Hospital; Hebei Key Laboratory of Molecular Oncology
1 shared publication
Latest Publications
- 4 May 2023
- Published by Taylor & Francis in Immunotherapy
- Vol. 15 (9) , 641-645
Fatal Cytokine-Release Syndrome in A Patient Receiving Toripalimab: A Case Report
Immune checkpoint inhibitors, a type of immunotherapy, have demonstrated optimal treatment efficacy in inducing durable antitumor responses in various cancers. Cytokine-release syndrome is a rare i... Plain language summary Immune checkpoint inhibitors (ICIs) have shown revolutionary efficacy in the treatment of multiple cancers. Cytokine-release syndrome (CRS) is a common and lethally adverse e...
- 4 May 2023
- Published by Taylor & Francis in Immunotherapy
- Vol. 15 (9) , 641-645
Fatal Cytokine-Release Syndrome in A Patient Receiving Toripalimab: A Case Report
Immune checkpoint inhibitors, a type of immunotherapy, have demonstrated optimal treatment efficacy in inducing durable antitumor responses in various cancers. Cytokine-release syndrome is a rare i... Plain language summary Immune checkpoint inhibitors (ICIs) have shown revolutionary efficacy in the treatment of multiple cancers. Cytokine-release syndrome (CRS) is a common and lethally adverse e...
- 9 June 2020
- Published by Springer Nature in Oncogene
- Vol. 39 (27) , 5056-5067
WSTF acetylation by MOF promotes WSTF activities and oncogenic functions
Williams syndrome transcription factor (WSTF) is a transcription factor and tyrosine kinase. WSTF overexpression promotes migration and proliferation of various cancers, and Ser158 (WSTFS158) phosphorylation plays an important role in this process. However, the role of the other posttranslational modifications of WSTF is unknown. Here, we report that lysine (K) 426 on WSTF is acetylated by MOF and deacetylated by SIRT1. Mechanistically, male-specific lethal (MSL) 1v1 interaction with WSTF facilitates its interaction with MOF for WSTF acetylation, which in turn promotes WSTFS158 phosphorylation. The kinase and transcriptional regulatory activity of WSTF were enhanced by acetylation. WSTFK426ac levels positively and significantly correlated with tumor size, histological grade, and age. Moreover, we demonstrated that acetylated WSTF promotes cancer cell proliferation, migration, invasion, and tumor formation. In conclusion, we identified the enzymes regulating WSTF K426 acetylation, and demonstrated an acetylation-dependent mechanism that modulates the activities of WSTF and contributes to tumorigenesis. Our findings provide new clues to study WSTF-mediated normal development and disease.
- 9 June 2020
- Published by Springer Nature in Oncogene
- Vol. 39 (27) , 5056-5067
WSTF acetylation by MOF promotes WSTF activities and oncogenic functions
Williams syndrome transcription factor (WSTF) is a transcription factor and tyrosine kinase. WSTF overexpression promotes migration and proliferation of various cancers, and Ser158 (WSTFS158) phosphorylation plays an important role in this process. However, the role of the other posttranslational modifications of WSTF is unknown. Here, we report that lysine (K) 426 on WSTF is acetylated by MOF and deacetylated by SIRT1. Mechanistically, male-specific lethal (MSL) 1v1 interaction with WSTF facilitates its interaction with MOF for WSTF acetylation, which in turn promotes WSTFS158 phosphorylation. The kinase and transcriptional regulatory activity of WSTF were enhanced by acetylation. WSTFK426ac levels positively and significantly correlated with tumor size, histological grade, and age. Moreover, we demonstrated that acetylated WSTF promotes cancer cell proliferation, migration, invasion, and tumor formation. In conclusion, we identified the enzymes regulating WSTF K426 acetylation, and demonstrated an acetylation-dependent mechanism that modulates the activities of WSTF and contributes to tumorigenesis. Our findings provide new clues to study WSTF-mediated normal development and disease.